According to the latest report from the Congolese Ministry of Health, released by the Xinhua news agency, as of October 11, there were 9,066 confirmed cases of Ebola and 4,381 deaths. This means that the mortality rate among confirmed cases is 48.3 percent. So far, 2,389 patients have recovered from the disease.
The epidemic, officially declared on May 15, has affected 65 health zones in seven provinces of the Democratic Republic of Congo. The Ituri province, in the east, remains the most affected, accounting for 73.8 percent of all confirmed cases. In the neighboring North Kivu province, the mortality rate among confirmed cases is as high as 57.1 percent.
The current epidemic is the largest and deadliest in the history of the Democratic Republic of Congo. Globally, it is only surpassed by the epidemic in West Africa from 2014 to 2016, which claimed more than 11,000 lives.
The epidemic is receding in some areas, but spreading in others
The Congolese Minister of Health, Roger Kamba, said at the beginning of October that the spread of Ebola is gradually concentrating in a smaller number of areas. In several previously affected regions, no new cases have been reported for weeks.
The World Health Organization (WHO) warns that the situation remains serious. Its Director-General, Tedros Adhanom Ghebreyesus, warned on October 7 that while the epidemic is weakening in some parts of the country, the number of infections continues to rise in others.
One of the biggest challenges remains the inadequate tracking of people who have come into contact with infected individuals. In addition, healthcare workers are struggling with a high number of deaths outside of specialized treatment centers, which complicates the control of further virus spread.
The situation is also complicated by long-standing security and humanitarian problems in the east of the country, limited access to healthcare, and the movement of people between affected areas.
Hope comes with new vaccine research
The current epidemic is caused by a variant of the Ebola virus known as Bundibugyo. There is currently no specifically approved vaccine or targeted treatment for this variant.
The Ervebo vaccine, which was approved for use against a different variant of Ebola, known as Zaire, is already being used in the fight against the infection. However, its effectiveness against the Bundibugyo virus has not yet been proven.
According to the latest situation report, as of October 11, 399 healthcare workers working on the front lines were vaccinated in the Haut-Uele province as part of research and special treatment procedures.
A significant breakthrough could now come with the upcoming clinical trial Tumaini, which means "hope" in Swahili.
The Coalition for Epidemic Preparedness Innovations (CEPI) announced on Tuesday, October 13, that preparations for the study are entering the final phase. Phase 2/3 clinical trials will evaluate the safety, immune response, and efficacy of several candidate vaccines against the Bundibugyo virus.
The study is expected to begin in the coming weeks, pending the necessary ethical and regulatory approvals. The Ervebo vaccine will likely be evaluated first. Later, new vaccines being developed specifically against this variant of the virus will also be included.
Congolese scientific institutions, the University of Antwerp, and international health organizations are collaborating on the research, with the support of CEPI and WHO.
The next few weeks will be crucial
Although the upcoming vaccine trials represent an important step, they will not provide an immediate solution to the current epidemic. Success will depend not only on the results of the clinical trials, but also on the ability of healthcare teams to quickly identify new cases, isolate infected individuals, and track their contacts.
The WHO emphasizes that cooperation with local communities and access to healthcare are also of crucial importance.
The development of an effective vaccine against the Bundibugyo virus could have a significant impact far beyond the borders of the Democratic Republic of Congo. It would strengthen the preparedness of healthcare systems for future epidemics of one of the most dangerous viral infections in the world.
Jaroslav Holý
